Embodiments described herein generally relate to: sensing and/or authentication using luminescence imaging; diagnostic assays, systems, and related methods; temporal thermal sensing and related methods; and/or to emissive species, such as those excitable by white light, and related systems and methods.

Embodiments described herein generally relate to: sensing and/or authentication using luminescence imaging; diagnostic assays, systems, and related methods; temporal thermal sensing and related methods; and/or to emissive species, such as those excitable by white light, and related systems and methods.

Embodiments described herein generally relate to: sensing and/or authentication using luminescence imaging; diagnostic assays, systems, and related methods; temporal thermal sensing and related methods; and/or to emissive species, such as those excitable by white light, and related systems and methods.

Embodiments described herein generally relate to: sensing and/or authentication using luminescence imaging; diagnostic assays, systems, and related methods; temporal thermal sensing and related methods; and/or to emissive species, such as those excitable by white light, and related systems and methods.

The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.

A field effect transistor (FET) biosensor for virus detection of a selected virus within a sample volume is disclosed. The FET comprises a semiconductor substrate, a source and drain electrode on the substrate, the electrodes spaced to form a channel. A gate electrode carried on the substrate and located in the channel between the source and drain electrodes. An insulating layer is coupled to a top surface of the gate electrode and a bottom surface of the source and drain electrodes, with an open channel above the insulating layer. A channel material is coupled to the insulating layer. Aptamers are oriented within the open channel to bind to the channel material and with the selected virus to enable a detection of the selected virus by the FET biosensor based on a change in drain-source current at a selected gate voltage.

In one embodiment, a method is provided comprising analyte testing on one or more types of samples.

A method for facilitating epidemiologic surveillance for a target disease such as Covid-19 includes a step of using an optical identifier such as a barcode or a numerical code to rapidly report de-identified test results to a central database. A rapid test device may be based on a direct flow point-of-care device comprising a porous membrane with at least one recombinant antigen applied thereto and procedural control. The recombinant antigen may comprise an epitope for detecting the target disease marker. The first optical identifier may be applied to the device and facilitate remote communication of the test results without the use of any specialized equipment.

Disclosed herein is the expression of beta-domain (Asp201-Gly339) of the VP2 protein (NCBI Acc. No. KT281984) of infectious bursal disease virus (IBDV), in codon optimized Rosetta 2 (DE3) strain of E. coli followed by its purification by affinity and gel filtration chromatography and use for development of dipstick and lateral flow strip for diagnosis of antibodies produced in chicken upon IBDV infection/vaccination.

Systems and methods are provided herein for rapid detection, separation, purification, and quantification of viral particles in a sample. According to some embodiments, a microfluidic device is provided for receiving the sample which may contain viral particles. An electrode of the microfluidic device may be used to generate dielectrophoretic (DEP) and/or electroosmotic (EO) forces acting on the sample. The applied DEP and/or EO forces may immobilize components of the sample on the surface of the electrode, may aggregate viral particles of the sample in one region of the microfluidic device, and may separate other components of the sample from the viral particles. The techniques may be performed rapidly, for example, in eight hours or less, and may not affect infectivity of the viral particles. In some embodiments, the sample may be labeled to enhance a response of one or more of the sample components to the DEP and/or EO forces.